COVID-19 is a mild infection for eight out of 10 people who get it. However for others it can lead to inflammation and eventually Acute Respiratory Distress Syndrome (ARDS) or Ventilator-Induced Lung Injury (VILI).
The challenge for medical professionals is that despite their best efforts, without a treatment for ARDS/VILI, even seemingly healthy patients presenting at trauma centers with other injuries, may die.
“ARDS is a vexing problem with a ~30-40% mortality rate but remains without any available FDA-approved ICU therapies.”Dr Joe “Skip” Garcia, Aqualung Therapeutics. 
What’s happening in the industry to address this?
Aqualung Therapeutics is just one example of a company who is advancing towards the clinic with a solution to combat serious unchecked inflammation, this offers a potential option in the treatment of COVID-19.
Aqualung have long recognized the need for an antibody-based solution to ARDS and have been working with Fusion Antibodies since 2018. In 2019 we carried out antibody humanization and followed up with a developability study enabling Aqualung to select the best possible lead candidate which they are now taking forward for Investigational New Drug (IND) trial.
We are also working with other clients to deliver antibodies to treat ARDS and more recently we have started work with a client to develop an antibody specifically against the coronavirus SARS-CoV-2.
The biotechnology industry is packed with great people and organizations striving to develop solutions for unmet medical needs. We have seen this community come together in the light of the COVID-19 pandemic. This is a time to celebrate the great work of our scientists and the achievements we make in bringing lifesaving treatments to patients around the world.
How can Fusion Antibodies help?
If you need support during this lock-down period, please continue to reach out to us. We are always happy to discuss any potential antibody development programme, but in particular at this present time we can offer support with:
o Expression of recombinant proteins in E. coli or mammalian cells for gram quantities and purification using FPLC
o Protein characterization and affinity measurements
o Antibody discovery from human B-cells using Next-Generation Sequencing (NGS) and repertoire analysis
o Stable cell line development for cGMP grade production cell lines
o Expression and purification of antibodies or antibody fragments from mammalian cell
o Antibody characterization and affinity measurements
Reach out to us on email firstname.lastname@example.org